Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Lisata Therapeutics Announces Research License with Catalent
08:00am, Tuesday, 15'th Apr 2025
BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative ther
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
02:24pm, Thursday, 16'th Jan 2025
Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said
Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
05:46pm, Wednesday, 18'th Dec 2024
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE: LII) will replace Catalent Inc. (NYSE: CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE: BILL) w
Novo Holdings completes $16.5 bln takeover of Catalent
09:08am, Wednesday, 18'th Dec 2024
Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfill
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
11:53am, Saturday, 14'th Dec 2024
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transacti
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expir
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction
12:06am, Saturday, 14'th Dec 2024
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Nov
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisati
Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction
01:08pm, Friday, 06'th Dec 2024
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Nov
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
01:05pm, Friday, 06'th Dec 2024
Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.
Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?
12:35pm, Thursday, 05'th Dec 2024
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says
12:37pm, Friday, 22'nd Nov 2024
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday.
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
12:43pm, Wednesday, 13'th Nov 2024
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matt
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
12:40pm, Wednesday, 13'th Nov 2024
Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up
10:11am, Wednesday, 06'th Nov 2024
CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours trading.
